Mohamed Hany, Bart Torensma, Anwar Ashraf Abouelnasr, Ahmed Zidan, Mohamed Ibrahim, Ann Samy Shafiq Agayby, Mohamed Hesham, Amel Elsheredy, Ghada Ahmed Abu-Sheasha
{"title":"Impact of bariatric surgery on the effectiveness of serological response after COVID-19 vaccination.","authors":"Mohamed Hany, Bart Torensma, Anwar Ashraf Abouelnasr, Ahmed Zidan, Mohamed Ibrahim, Ann Samy Shafiq Agayby, Mohamed Hesham, Amel Elsheredy, Ghada Ahmed Abu-Sheasha","doi":"10.1007/s00423-022-02516-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The primary objective of the current study is to determine whether bariatric surgery reversed the negative impact of obesity on the serological response after the COVID-19 vaccination. This objective is achieved in two steps: (a) quantifying the negative impact of obesity on the serological response after COVID-19 vaccination if it is present, and (b) testing whether bariatric surgery reversed this impact. The secondary objective was to monitor the occurrence of adverse events.</p><p><strong>Methods: </strong>This is a prospective cohort study between May 2021 and August 2021 on the strength of serological response after COVID-19 vaccination. Patients were classified into three groups. Group A (controls with normal or overweight), Group B (bariatric patients pre-operative), and Group C (bariatric patients post-operative). Quantitative antibodies against SARS‑CoV‑2 RBD with a strong neutralizing capacity were quantified from sera after at least 2 weeks post-vaccination.</p><p><strong>Results: </strong>Of the 276 participants, Group A had n = 73, Group B had n = 126, and Group C had n = 77 patients. Overall, a strongly positive vaccine serological response was observed among 86% in group A, 63% in Group B, and 88% in Group C. Group C showed 5.33 times [95% CI 2.15 to 13.18] higher immune response than group B. Mild to moderate adverse events occurred in 30.1% [95% CI 24.7 to 35.9] of the study samples. Adverse events with the whole virus, mRNA, and vector vaccines occurred in 25%, 28%, and 37%, respectively.</p><p><strong>Conclusion: </strong>Vaccinating and bariatric surgery are safe and effective treatments in the serological response in patients who suffer from obesity.</p>","PeriodicalId":50368,"journal":{"name":"Industrial and Engineering Chemistry","volume":"41 1","pages":"2337-2346"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050480/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Industrial and Engineering Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00423-022-02516-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The primary objective of the current study is to determine whether bariatric surgery reversed the negative impact of obesity on the serological response after the COVID-19 vaccination. This objective is achieved in two steps: (a) quantifying the negative impact of obesity on the serological response after COVID-19 vaccination if it is present, and (b) testing whether bariatric surgery reversed this impact. The secondary objective was to monitor the occurrence of adverse events.
Methods: This is a prospective cohort study between May 2021 and August 2021 on the strength of serological response after COVID-19 vaccination. Patients were classified into three groups. Group A (controls with normal or overweight), Group B (bariatric patients pre-operative), and Group C (bariatric patients post-operative). Quantitative antibodies against SARS‑CoV‑2 RBD with a strong neutralizing capacity were quantified from sera after at least 2 weeks post-vaccination.
Results: Of the 276 participants, Group A had n = 73, Group B had n = 126, and Group C had n = 77 patients. Overall, a strongly positive vaccine serological response was observed among 86% in group A, 63% in Group B, and 88% in Group C. Group C showed 5.33 times [95% CI 2.15 to 13.18] higher immune response than group B. Mild to moderate adverse events occurred in 30.1% [95% CI 24.7 to 35.9] of the study samples. Adverse events with the whole virus, mRNA, and vector vaccines occurred in 25%, 28%, and 37%, respectively.
Conclusion: Vaccinating and bariatric surgery are safe and effective treatments in the serological response in patients who suffer from obesity.